Shares of Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report) dropped 3.5% during trading on Wednesday . The company traded as low as $3.25 and last traded at $3.35. Approximately 4,633 shares were traded during trading, a decline of 73% from the average daily volume of 17,048 shares. The stock had previously closed at $3.47.
Wall Street Analysts Forecast Growth
Separately, Guggenheim began coverage on shares of Nanobiotix in a research report on Wednesday, August 28th. They set a “buy” rating and a $12.00 target price on the stock.
Read Our Latest Stock Report on Nanobiotix
Nanobiotix Trading Down 3.5 %
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than Nanobiotix
- When to Sell a Stock for Profit or Loss
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Why Are Stock Sectors Important to Successful Investing?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
